Pomegra
Emerald, the London preventive-health startup founded by ex-Revolut staff, raised £1.4M in October 2026, half of it an Innovate UK grant, taking total funding to £2.9M.
Key Takeaways
- Emerald raised £1.4M: £700,000 from Innovate UK and £700,000 from venture investors.
- Total funding reaches £2.9M. Valuation and round stage were not disclosed.
- Membership grew tenfold in 2026, and the company aims for 1M members within three years.
Lead
Emerald, a London-based preventive healthcare company founded by former Revolut employees, announced £1.4M in new funding on 20 October 2026. The company said the round takes total funding to date to £2.9M. Half the money, £700,000, is a grant from Innovate UK, the government innovation agency, which makes it Emerald's second award from that body. The remaining £700,000 came from venture investors.
Who Backed the Round?
All existing investors took part, joined by Boost Capital Partners, which led Emerald's January 2026 pre-seed round. Two new backers, Sequel and Highgoal Capital, also came in. No lead investor was named for this round, and Emerald did not state a valuation or label the round's stage. The company said only that its valuation rose from the previous round.
That leaves the equity half of the raise small. A £700,000 cheque split among existing holders and three named funds suggests an extension-sized round rather than a priced step up. The grant carries no dilution, which flatters the headline figure.
What Does Emerald Actually Sell?
Emerald sells a membership that combines blood screening with a digital health record and access to doctors. Members take lab tests at partner locations, then see results, wearable data and health history in one app. A GP can diagnose, prescribe and refer, with AI tools supporting the monitoring.
The January round described a baseline blood test covering more than 115 biomarkers at over 50 UK locations. Emerald has also secured registration with the Care Quality Commission, which allows it to operate as a regulated medical provider. Pricing has not been disclosed. The product competes with consumer testing services and private GP subscriptions, and it positions itself as the clinical layer on top of the data.
How Fast Is Emerald Growing?
Emerald reports that membership increased tenfold in 2026 and that it has processed more than 100,000 laboratory tests. It did not publish an absolute member count, so the tenfold figure has no stated base. The 1M-member target over three years is the number that matters, and the distance from today's undisclosed base to seven figures is the unverifiable part of the story.
The company's history is short. It was founded in 2024 by Alexander Badalyan (CEO), Anton Shchipanov (CTO) and Dr Dan McNally (Chief Medical Officer). Earlier funding included a £625,000 launch round in 2024 and a pre-seed in January 2026 reported at £1.5M, led by Boost Capital Partners with Mark Fountain and Granatus Ventures participating.
Why Does the Revolut Pedigree Matter?
The Revolut link matters because the pitch borrows a consumer-fintech playbook: one app, one account, one view of the user. Badalyan and Shchipanov are applying that to health data, which is fragmented across labs, GPs and wearables. The clinical credibility sits with McNally and the CQC registration.
The pedigree does not change the economics of the sector. Preventive health has drawn many funded entrants, and retention depends on whether members keep testing after the first result. A tenfold rise in membership says little about renewal rates, which Emerald has not published.
What Will the Money Fund?
Emerald said the proceeds go to commercial expansion, product development, clinical services and further work on its AI applications. In an October statement the company said people want to understand what their results mean and what steps improve long-term health, guided by trusted medical experts.
The use of funds is conventional. The split between sales spending and clinical hiring is not disclosed, and it will shape margins, since doctor time is the costly input in a GP-led model.
What Comes Next?
A realistic read is a further raise within 12 to 18 months. Reaching 1M members would require a step change in distribution, likely through employers, insurers or partnerships, none of which the company has announced. Regulatory scrutiny of AI in clinical settings and data handling for health records will also rise as membership grows.
Outlook
Emerald enters its next phase with £2.9M raised, a regulated clinical offering and a stated goal of 1M members by roughly 2029. The round is modest, half grant-funded and light on disclosed terms. The next test is whether growth from an undisclosed base converts into paying, renewing members at a cost that supports a larger Series A.
